Aggrastat(r), lowers incidence of heart attack, in patients who respond poorly to aspirin or clopidogrel, after elective coronary angioplasty

Antiplatelet medicine, AGGRASTAT® (tirofiban HCL), a glycoprotein IIb/IIIa inhibitor, has been shown to significantly lower the incidence of heart attack after elective coronary angioplasty, in patients with coronary artery disease who have shown poor response to standard oral antiplatelet agents such as aspirin and clopidogrel.1 These results were announced at the Annual European Society of Cardiology Congress in Munich, Germany. (Source: Cardiovascular / Cardiology News From Medical News Today)

 

: Find out how you can get your across here by sponsoring this news feed.